|
Market Closed -
Other stock markets
|
After hours 04:22:50 pm | |||
| 218.21 USD | -0.21% |
|
217.84 | -0.17% |
| 02:20pm | Equities Slump, Gold Surges Intraday After Trump's Latest Tariff Threat | MT |
| 12:09pm | Global drugmakers rush to boost US presence as tariff threat looms | RE |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 82.58B | 93.78B | 94.94B | 85.16B | 88.82B | |||||
Total Revenues | 82.58B | 93.78B | 94.94B | 85.16B | 88.82B | |||||
Cost of Goods Sold, Total | 28.33B | 29.76B | 30.99B | 26.24B | 27.04B | |||||
Gross Profit | 54.26B | 64.02B | 63.95B | 58.92B | 61.78B | |||||
Selling General & Admin Expenses, Total | 22.08B | 24.06B | 23.6B | 20.17B | 21.95B | |||||
R&D Expenses | 12.16B | 14.71B | 14.6B | 15.08B | 17.23B | |||||
Other Operating Expenses, Total | 34.24B | 38.77B | 38.21B | 35.25B | 39.18B | |||||
Operating Income | 20.01B | 25.25B | 25.75B | 23.66B | 22.6B | |||||
Interest Expense, Total | -201M | -183M | -276M | -772M | -755M | |||||
Interest And Investment Income | 111M | 53M | 490M | 1.26B | 1.33B | |||||
Net Interest Expenses | -90M | -130M | 214M | 489M | 577M | |||||
Currency Exchange Gains (Loss) | -209M | -236M | -328M | -366M | -214M | |||||
Other Non Operating Income (Expenses) | 469M | 991M | 1.83B | 1.66B | 1.48B | |||||
EBT, Excl. Unusual Items | 20.18B | 25.87B | 27.46B | 25.45B | 24.45B | |||||
Restructuring Charges | -447M | -452M | -521M | -798M | -269M | |||||
Merger & Related Restructuring Charges | - | -117M | -300M | -200M | -1.2B | |||||
Gain (Loss) On Sale Of Investments | 972M | 1.09B | -700M | -600M | -300M | |||||
Gain (Loss) On Sale Of Assets | 111M | 617M | 380M | 117M | 226M | |||||
Asset Writedown | -190M | -936M | -1.22B | -1.3B | -405M | |||||
In Process R&D Expenses | -181M | -900M | -783M | -313M | -211M | |||||
Legal Settlements | -5.1B | -2.3B | -900M | -6.9B | -5.5B | |||||
Other Unusual Items | 1.15B | -100M | -1.7B | -400M | -100M | |||||
EBT, Incl. Unusual Items | 16.5B | 22.78B | 21.72B | 15.06B | 16.69B | |||||
Income Tax Expense | 1.78B | 1.9B | 3.78B | 1.74B | 2.62B | |||||
Earnings From Continuing Operations | 14.71B | 20.88B | 17.94B | 13.33B | 14.07B | |||||
Earnings Of Discontinued Operations | - | - | - | 21.83B | - | |||||
Net Income to Company | 14.71B | 20.88B | 17.94B | 35.15B | 14.07B | |||||
Net Income - (IS) | 14.71B | 20.88B | 17.94B | 35.15B | 14.07B | |||||
Net Income to Common Incl Extra Items | 14.71B | 20.88B | 17.94B | 35.15B | 14.07B | |||||
Net Income to Common Excl. Extra Items | 14.71B | 20.88B | 17.94B | 13.33B | 14.07B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 5.59 | 7.93 | 6.83 | 13.88 | 5.84 | |||||
Basic EPS - Continuing Operations | 5.59 | 7.93 | 6.83 | 5.26 | 5.84 | |||||
Basic Weighted Average Shares Outstanding | 2.63B | 2.63B | 2.63B | 2.53B | 2.41B | |||||
Net EPS - Diluted | 5.51 | 7.81 | 6.73 | 13.72 | 5.79 | |||||
Diluted EPS - Continuing Operations | 5.51 | 7.81 | 6.73 | 5.2 | 5.79 | |||||
Diluted Weighted Average Shares Outstanding | 2.67B | 2.67B | 2.66B | 2.56B | 2.43B | |||||
Normalized Basic EPS | 4.79 | 6.14 | 6.54 | 6.28 | 6.35 | |||||
Normalized Diluted EPS | 4.72 | 6.05 | 6.44 | 6.21 | 6.29 | |||||
Dividend Per Share | 3.98 | 4.19 | 4.45 | 4.7 | 4.91 | |||||
Payout Ratio | 71.23 | 52.84 | 65.11 | 33.48 | 84.05 | |||||
American Depositary Receipts Ratio (ADR) | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | |||||
Supplemental Items | ||||||||||
EBITDA | 27.24B | 32.64B | 32.72B | 30.77B | 29.94B | |||||
EBITA | 24.71B | 29.95B | 30.05B | 28.16B | 27.1B | |||||
EBIT | 20.01B | 25.25B | 25.75B | 23.66B | 22.6B | |||||
EBITDAR | 27.54B | 32.94B | 33.02B | 30.97B | 30.14B | |||||
Effective Tax Rate - (Ratio) | 10.81 | 8.33 | 17.42 | 11.53 | 15.71 | |||||
Current Domestic Taxes | 1.03B | 1.52B | 2.38B | 2.7B | 2.2B | |||||
Current Foreign Taxes | 1.9B | 2.45B | 3.07B | 3.09B | 2.6B | |||||
Total Current Taxes | 2.92B | 3.98B | 5.45B | 5.8B | 4.8B | |||||
Deferred Domestic Taxes | -76M | 583M | -2.08B | -3.44B | -2.54B | |||||
Deferred Foreign Taxes | -1.06B | -2.66B | 418M | -619M | 356M | |||||
Total Deferred Taxes | -1.14B | -2.08B | -1.66B | -4.06B | -2.18B | |||||
Normalized Net Income | 12.62B | 16.17B | 17.17B | 15.91B | 15.28B | |||||
Interest Capitalized | 63M | 49M | 49M | 70M | 79M | |||||
Non-Cash Pension Expense | -590M | -798M | -1.37B | -1.57B | -1.17B | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | 2.1B | 2.7B | 2.1B | 500M | 600M | |||||
Selling and Marketing Expenses | 2.1B | 2.7B | 2.1B | 500M | 600M | |||||
Research And Development Expense From Footnotes | 12.34B | 15.61B | 15.39B | 15.4B | 17.44B | |||||
Net Rental Expense, Total | 300M | 300M | 300M | 200M | 200M | |||||
Imputed Operating Lease Interest Expense | 19.48M | 15.66M | 20.6M | 37.86M | 39.09M | |||||
Imputed Operating Lease Depreciation | 281M | 284M | 279M | 162M | 161M | |||||
Stock-Based Comp., Other (Total) | 1B | 1.14B | 1.14B | 1.16B | 1.18B | |||||
Total Stock-Based Compensation | 1B | 1.14B | 1.14B | 1.16B | 1.18B |
- Stock Market
- Equities
- JNJ Stock
- Financials Johnson & Johnson
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
















